Expression levels of MALAT-1 in the plasma of patients with breast cancer and its clinical significance
YANG Hui1, XU Wen-lin1, SU Zhao-liang2, CHEN Qi1
(1. Department of Mammary, the Fourth Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001; 2. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013, China)
Abstract：Objective: To investigate the expression levels of long noncoding RNA metastasisassociated lung adenocarcinoma transcript 1 (MALAT1) in the plasma of patients with breast cancer and its clinical significance. Methods: MALAT1 levels in the 60 pairs of human breast cancer tissue and matched paracarcinoma tissues, in the plasma of 60 breast cancer patients and 60 plasma samples from the patients with breast fibroadenoma were detected by using quantitative realtime PCR. The correlations of plasma MALAT1 level with the clinicopathological features of the breast cancer patients were analyzed. The content of CA125 and CA153 in plasma was detected by electrochemiluminescence; and a multivariate Logistic regression model was established to analyze the diagnostic efficacy of plasma MALAT1, CA125, CA153 and the diagnostic value of three indicators combined. Results: MALAT1 expression in breast cancer tissue was higher than that in adjacent breast tissue. Compared with the breast fibroadenoma group, breast cancer patients had increased expressions of MALAT1 in plasma, and plasma MALAT1 level was significantly correlated with triplenegative breast cancer and lymph node metastasis(P<0.05). ROC curve and the multivariable Logistic regression model showed that the area under ROC curve(AUC) of plasma MALAT1 was 0.961(P<0.001) for breast cancer diagnosis, with a diagnostic sensitivity and a specificity of 96.7% and 93.3%, respectively. The diagnostic power and specificity of plasma MALAT1 was much higher than those of CA125 (AUC=0.618, P=0.022) and CA153(AUC=0.623, P=0.016); and the combination of the 3 indicators had higher sensitivity(98.3%) than the single indicator. Conclusion: MALAT1 was highly expressed in the plasma of breast cancer patients, and may serve as a potential biomarker for breast cancer diagnosis.
杨卉1， 许文林1， 苏兆亮2， 陈琦1. 肺腺癌转移相关转录本1在乳腺癌患者血浆中的表达及临床意义[J]. 江苏大学学报:医学版, 2018, 28(01): 51-55,91.
YANG Hui1, XU Wen-lin1, SU Zhao-liang2, CHEN Qi1. Expression levels of MALAT-1 in the plasma of patients with breast cancer and its clinical significance. Journal of Jiangsu University(Medicine Edition), 2018, 28(01): 51-55,91.
［1］Hong CS, Graham NA, Gu W, et al. MCT1 modulates cancer cell pyruvate export and growth of tumors that coexpress MCT1 and MCT4\[J\]. Cell Rep, 2016, 14(7): 1590-1601.［2］Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012\[J\]. Int J Cancer, 2015, 136(5):E359-E386.［3］Duffy MJ, Evoy D, McDermott EW. CA 153: uses and limitation as a biomarker for breast cancer\[J\]. Clin Chim Acta, 2010, 411(23/24): 1869-1874.［4］叶蓓,柳光宇,陆劲松,等.常用的乳腺癌血清肿瘤标志物在早期诊断中的应用价值不高\[J\].中国癌症杂志，2009，19(10)：807-808.［5］郭德阳, 陈雷, 余正. 循环肿瘤细胞的检测及其在乳腺癌中的应用研究进展\[J\]. 中华临床医师杂志(电子版), 2015, 9(21):3992-3996.［6］Shaker O, Maher M, Nassar Y, et al. Role of microRNAs29b2,155, 197 and 205 as diagnostic biomarkers in serum of breast cancer females\[J\]. Gene, 2015, 560 (1): 77-82.［7］Müller V, Gade S, Steinbach B, et al. Changes in serum levels of miR21, miR210, and miR373 in HER2positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial\[J\]. Breast Cancer Res Treat, 2014, 147(1): 61-68.［8］Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer\[J\].Theranostics, 2015, 5(10): 1122-1143.［9］Huang X, Yuan T, Tschannen M, et al. Characterization of human plasmaderived exosomal RNAs by deep sequencing\[J\]. BMC Genomics, 2013, 14: 319.［10］Schwarzenbach H, Hoon DS, Pantel K. Cellfree nucleic acids as biomarkers in cancer patients\[J\]. Nat Rev Cancer, 2011, 11(6): 426-437.［11］Van der Vaart M, Pretorius PJ. Circulating DNA. Its origin and fluctuation\[J\]. Ann N Y Acad Sci, 2008, 1137: 18-26.［12］Tripathi V, Shen Z, Chakraborty A, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor BMYB\[J\]. PLoS Genet, 2013, 9(3):e1003368.［13］Zheng HT, Shi DB, Wang YW, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer\[J\]. Int J Clin Exp Pathol, 2014, 7(6):3174-3181.［14］Gutschner T, Hmmerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells\[J\]. Cancer Res, 2013, 73(3):1180-1189.［15］Han Y, Liu Y, Nie L, et al. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing
2018, Vol. 28 
